16:03 EDT Evaxion Biotech (EVAX) files $50M ordinary shares offering Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses.

In a report released today, Gena Wang from Barclays maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price target of $94.00. The company’s shares closed yesterday at ...

Cash and Equivalents: $1.1 billion at the end of 2024. Legend Biotech Corp (NASDAQ:LEGN) reported a 110% year-over-year increase in net trade sales of CARVYKTI, reaching approximately $334 million ...

Legend Biotech Corp. reported a robust performance for Q4 2024, driven by a significant increase in CARVICTI sales. The company achieved net sales of $334 million for CARVICTI, marking a 110% year ...

A recent study published in Advanced Functional Materials explores a novel method for functionalizing glass using ultrasonication of aryl diazonium salts. Earlier methods for glass functionalization, ...

Full-Year Loss Per Share: $0.41 for 2024. Oncolytics Biotech Inc (NASDAQ:ONCY) reported outstanding final data in the BRACELET-1 breast cancer study, exceeding expectations. The company has ...

LOS ANGELES (AP) — LOS ANGELES (AP) — Puma Biotechnology Inc. (PBYI) on Thursday reported fourth-quarter profit of $19.3 million. On a per-share basis, the Los Angeles-based company said it ...

Agenus Chief Medical Officer Dr. Steven O'Day joined Fierce's Chris Hayden on a recent sponsored episode of The Top Line podcast to discuss the evolving landscape of cancer immunotherapy.

SOMERSET, N.J. - Legend Biotech Corporation (NASDAQ:LEGN) reported fourth quarter 2024 financial results that exceeded analyst expectations, driven by strong sales of its multiple myeloma ...

Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will ...

Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08. Operator: Good morning, and welcome to Oncolytics Biotech Inc.’s fourth quarter and full ...